LIDOCAINE;
LOCAL ANESTHETIC AGENT;
UNCLASSIFIED DRUG;
VISTHESIA;
ANALGESIA;
CATARACT;
CLINICAL TRIAL;
CONJUNCTIVA DISEASE;
CONJUNCTIVAL REDNESS;
DRUG DOSAGE FORM COMPARISON;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
LETTER;
PHACOEMULSIFICATION;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
VISUAL ANALOG SCALE;
Effect of application duration of 2% lidocaine jelly on aqueous lidocaine concentration for topical anesthesia in cataract surgery
DOI 10.1007/s00417-005-0247-5
AK Kwok TY Lai VY Lee YS Yeung KO Chu CC Pang 2006 Effect of application duration of 2% lidocaine jelly on aqueous lidocaine concentration for topical anesthesia in cataract surgery Graefes Arch Clin Exp Ophthalmol 244 1096 1100 10.1007/s00417-005-0247-5 1:CAS:528:DC%2BD28XotlChsbc%3D 16485111 (Pubitemid 44269586)
Mydriasis with different preparations of topically administered lidocaine hydrochloride
10.1016/j.jcrs.2008.10.034 19185243
M Claesson M Johansson A Behndig 2009 Mydriasis with different preparations of topically administered lidocaine hydrochloride J Cataract Refract Surg 35 277 281 10.1016/j.jcrs.2008.10.034 19185243
AstraZeneca Canada Inc Mississauga, Ontario, Canada. Available at
AstraZeneca Canada Inc. Xylocaine® Jelly 2% Prescribing Information. Mississauga, Ontario, Canada. Available at: http://www.astrazeneca.ca/documents/ ProductPortfolio/XYLOCAINE%20Jelly-PM-en.pdf (Accessed on July 20, 2009)